News from prometheus laboratories inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

May 28, 2015, 08:00 ET

PROCLAIM(SM) Patient Registry Data Demonstrates Safety and Efficacy of Proleukin® (aldesleukin) When Sequenced with Immune Checkpoint Inhibitors in Metastatic Melanoma

Prometheus Laboratories, Inc. announced today the presentation of data from patients enrolled in the PROCLAIMSM national patient registry,...

May 28, 2015, 08:00 ET

PROCLAIM Patient Registry Data Demonstrate Survival Benefit of First-line Proleukin® Therapy in Patients with Metastatic Renal Cell Carcinoma

 Prometheus Laboratories, Inc. announced today the presentation of updated data from the PROCLAIMSM national patient registry in which...

May 15, 2015, 08:00 ET

New Data Show Proleukin® (aldesleukin) Improves Patient Outcomes as First-Line Therapy for the Treatment of Patients with Metastatic Melanoma or Metastatic Renal Cell Carcinoma

 Prometheus Laboratories Inc. today announced the acceptance of data from three clinical studies by the American Society of Clinical Oncology...

May 31, 2014, 08:00 ET

PROCLAIM(SM) National Patient Registry Analysis Shows Improved Median Overall Survival in Patients with Metastatic Melanoma Treated with High-Dose Interleukin-2 (HD IL-2)

 Prometheus Laboratories Inc. announced today that data from the PROCLAIMSM national patient registry retrospective cohort document an...

May 30, 2014, 08:00 ET

PROCLAIM(SM) Patient Registry Data Show Extension of Overall Survival Benefits Beyond Complete and Partial Responders in Metastatic Renal Cell Carcinoma Patients Treated with High-Dose Interleukin-2 (HD IL-2)

 Prometheus Laboratories Inc. announced today that analysis of data from the PROCLAIMSM national patient registry retrospective cohort shows...

Oct 10, 2013, 09:15 ET

Prometheus Laboratories Inc. Announces Inclusion of Proleukin® (Aldesleukin for Injection) / Interleukin?2 in SITC Guidelines for Treatment of Cutaneous Melanoma

 Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announces the inclusion of Proleukin® (aldesleukin for...

Sep 19, 2013, 09:00 ET

Prometheus Laboratories Appoints Chief Executive Officer

Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company announced today that Ms. Lisa Miller has been appointed to the...

May 30, 2013, 09:20 ET

Prometheus Laboratories Launches PROCLIVITY 02, a Phase IV Multi-Center Study Comparing the Sequence of Proleukin® (Aldesleukin for Injection) and Yervoy® (Ipilimumab) in Patients with Metastatic Melanoma

Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announces that PROCLIVITY02, a multi-center study comparing the...

May 22, 2013, 16:32 ET

Prometheus Laboratories Presents New Data On Growing IBD Diagnostic Portfolio At Digestive Disease Week 2013

Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announced today the eighteen abstracts relating to its proprietary...

May 09, 2013, 12:46 ET

Prometheus Laboratories Inc. Launches PROCLIVITY(SM) 01 Clinical Trial of Proleukin® (Aldesleukin for Injection) Plus Vemurafenib Therapy in Patients with Metastatic Melanoma

 Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announces that PROCLIVITY 01, a multi-center...

Apr 30, 2013, 09:00 ET

Prometheus Launches New Adalimumab Drug And Antibody Levels Monitoring Test

Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announced today the US market launch of its proprietary new test,...

Oct 22, 2012, 09:00 ET

New Data Support Use Of PROMETHEUS® Anser™ IFX Assay In Managing infliximab Treatment Failure Among Inflammatory Bowel Disease Patients

 Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, will present five abstracts at the American College of...

Jul 31, 2012, 09:10 ET

Prometheus Launches New Monitoring Test To Help Guide Inflammatory Bowel Disease Management

Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announced today the market launch of its proprietary new...

May 22, 2012, 11:15 ET

New Data Support Role of Prometheus Laboratories' Novel Assay in Optimizing IBD Treatment Management

 Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announced today the thirteen abstracts relating to its...

Feb 07, 2012, 09:10 ET

Prometheus Signs Research & Collaboration Agreement with Leading Worldwide Pharmaceutical Company

 Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced the execution of a research and...

Feb 03, 2012, 09:10 ET

Prometheus Announces New Chief Commercial Officer

 Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced the appointment of Anthony J. Yost as Senior...

Nov 14, 2011, 11:19 ET

Prometheus Announces New Chief Medical Officer

Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced the appointment of Dr. Peter Heseltine as Senior...

Oct 24, 2011, 08:00 ET

Prometheus Launches Next Generation IBD Diagnostic Test

Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced the commercial launch of its proprietary...

May 24, 2011, 01:30 ET

Prometheus Announces Agreement to be Acquired by Nestle Health Science

Prometheus Laboratories Inc., ("Prometheus") a specialty pharmaceutical and diagnostic company, today announced that it has entered into a...

May 02, 2011, 06:00 ET

Prometheus Obtains Exclusive US Commercialization Rights for RENCAREX®

Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced that it has signed an exclusive agreement with...